OxfordOxford Mon - Fri 09:00-17:00 +44(0)1865-600222
LibPubMedia1@gmail.com
OxfordOxford Mon - Fri 09:00-17:00 +44(0)1865-600222
LibPubMedia1@gmail.com
J Venom Res
Open-access
Aptamers
Open-access
Aptamers 2018
11-12 April 2018, Oxford
Submit a manuscript

Speakers & Agenda

Day 1:

————————————————————

14.00: Registration, welcome coffee, networking, exhibition

Session 1: Chair Dr Mark Behlke

Hannon

15.00: Dr Greg Hannon – Keynote address
Cold Spring Harbor Laboratory & the Cancer Research UK Cambridge Institute
Title: Small RNAs and mammalian genomics

15.50: Q&A with Dr Hannon

16.00: Dr Anna Zampetaki
Lecturer in Cardiovascular Biology, King’s College London, The James Black Centre, London, UK
Title: Circulating microRNA networks as biomarkers in cardiovascular disease

16.30: Refreshment break

17.00: Dr Mark Perry
Research Fellow on Airway Disease, National Heart & Lung Institute, Imperial College London, London, UK
Title: MicroRNAs and lncRNAs in lung disease

17.30: Professor Chris Murphy
Kennedy Institute of Rheumatology, Roosevelt Drive, Headington, NDORMS, University of Oxford, Oxford, UK
Title: MicroRNAs in cartilage health and disease 

18.00: Dr Dmitry Samarsky
Executive Vice President, Technology & Business Development, RiboBio Co, China
Title: RNAi therapeutics: from discovery to manufacturing

18.30: Close of Day 1

————————————————————

Session 2: Chair Dr David Carter

09.00: Dr Sandor Batkai
Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany
Title: Non-coding RNAs in cardiac disease

09.30: Dr Mark Behlke
Chief Scientific Officer, Integrated DNA Technologies, USA
Title: Influence of Intracellular Localization on lncRNA Knockdown

10.00: Dr Ryan Raver
Sigma-Aldrich, USA
Title: The Future of RNAi Screening: Complementary Technologies and Improvements

10.30: Refreshment break, networking, posters, exhibition

11.15: Professor Tudor A Fulga
Associate Professor of Genome Biology, Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxord, UK
Title: Deciphering miRNA-target regulation by site-specific genome engineering 

11.45: Dr Annaleen Vermeulen
Senior Scientist, GE Healthcare/Dharmacon, Lafayette, CO, USA
Title: The Utility of CRISPR-Cas9 System Employing Synthetic RNAs to Validate Hits from an RNAi Functional Screen

12.15: Professor Stephen Hart
Experimental and Personalised Medicines, UCL Institute of Child Health, London, UK
Title: Targeted nanocomplex formulations for siRNA therapy

12.45: Lunch break, posters, exhibition

Session 3: Chair Dr Dmitry Samarsky

14.00: Dr Raymond Schiffelers
Associate Professor, Clinical Chemistry and Haematology, Department of Pharmaceutical Sciences, UMCU,  UTRECHT, The Netherlands
Title: In vivo delivery of therapeutic RNAs

14.30: Dr Tobias Poehlmann
Friedrich-Schiller-University of Jena, Spin-off project “Intelligent siRNA”, Jena, Germany
Title: Development of Tumor-toxic miRNA mimics 

15.00: Professor Andrew Miller
Founder and Chief Scientific Officer, GlobalAcorn Ltd (Advanced Therapeutics), UK, and Visiting Professor, King’s College London, UK
Title: Functional delivery of RNAi effectors; the universal challenge facing RNAi therapeutics

15.30: Refreshment break, networking, posters, exhibition

16.15: Dr Graeme Doran
Director of Genomic Assays, Firefly BioWorks Inc, One Kendall Square, Cambridge, MA, USA
Title: High throughput direct detection of miRNA from mammalian biofluids

16.35: Professor Dr Georg Sczakiel
Professor and Director, Institute of Molecular Medicine, University of Luebeck, Germany
Title: TBA

17.05: Professor Ian Blagbrough
Professor, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
Title: TBA

17.35: : Panel discussion: What is the future of small RNAs in therapy?

18.30: Close of Day 2

19.00: Networking dinner (by invitation or prior booking only)

 —————————————–

Day 3

Session 6:

9.00: Professor Martin Bushell
Deputy Director and MRC Senior Research Fellow, MRC Toxicology Unit, Leicester, UK
Title: The complexity of small RNA-mediated gene silencing

9.30: Dr Nicholas Dibb
Reader, Faculty of Medicine, Department of Surgery and Cancer, Imperial College London, UK
Title: The functional and evolutionary importance of isomiRs

10.00: Refreshment break, networking, posters, exhibition

10.30: Dr Iris Lavon
Leslie and Michael Gaffin Center for Neuro-Oncology and Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Title: Circulating miR-10b and miR-21 reflect the antiangiogenic effect of bevacizumab treatment in patients with glioblastoma (GBM)

11.00: Professor Gerry Melino
Head of ‘Apoptosis & Cancer’ Section, MRC Toxicology Unit, Leicester, UK
Title: The role of microRNAs in epithelial stemness

11.30: Dr Mark S Wilson
Group Leader, Division of Molecular Immunology, National Institutes for Medical Research. MRC, London, UK
Title: MicroRNAs in immune cells

12.00: Dr Dave Carter
Senior Lecturer, Oxford Brookes University, Oxford, UK
Title: Exosomes and miRNAs; potential star players in the response to cancer therapy 

 

12.30: Dr M Zeeshan Danish
Division of Drug Delivery and Tissue Engineering, School of Pharmacy, University of Nottingham, Nottingham, UK
Title: Formulation Optimization and Characterization of Novel Bio-reducible Cross-linked siRNA Polyplexes for Gene silencing

 

12.30: Close of conference